Jennifer O Stasik, MD
Medical Oncology · Tulsa, OKNPI 1447385091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Johnson & Johnson at 29.1% of the total. 2025 is the largest year on record at $1,946, more than ten times the $60 reported in 2019.
Across 145 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$875
- Pfizer$358
- AstraZeneca$237
- Novartis$213
- Inari Medical, Inc.$181
- Daiichi Sankyo Inc.$119
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,74191%
- Education$2639%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 42 | $875 |
| Pfizer | 26 | $358 |
| AstraZeneca | 12 | $237 |
| Novartis | 9 | $213 |
| Inari Medical, Inc. | 1 | $181 |
| Daiichi Sankyo Inc. | 5 | $119 |
| Incyte Corporation | 5 | $106 |
| Tersera Therapeutics LLC | 4 | $91 |
| Array Biopharma Inc | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Fresenius Kabi USA, LLC | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Sanofi | 2 | $46 |
| AbbVie | 2 | $42 |
| Stemline Therapeutics Inc. | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Bayer | 1 | $29 |
| Amgen | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Acrotech Biopharma Inc. | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $19 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Geron Corporation | 1 | $19 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Biocon Biologics Inc | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Penumbra, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IdhifaEnasidenib Mesylate | 13 | $513,279 |
| ImbruvicaIbrutinib | 29 | $511,388 |
| PromactaEltrombopag Olamine | 22 | $295,301 |
| JakafiRuxolitinib Phosphate | 15 | $263,676 |
| CalquenceAcalabrutinib Maleate | 16 | $248,297 |
| IbrancePalbociclib | 14 | $219,557 |
| VenclextaVenetoclax | 12 | $185,071 |
| Letrozole | 339 | $5,802 |
| Imatinib Mesylate | 20 | $3,528 |
| Exemestane | 19 | $1,896 |
| Prochlorperazine Maleate | 98 | $1,324 |
| Dexamethasone | 38 | $912 |
| Ondansetron Hcl | 82 | $799 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $403 |
| Hydroxyurea | 11 | $179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta | $213 | $295,30122 claims |
| Incyte CorporationJakafi | $106 | $263,67615 claims |
| AstraZenecaCalquence | $237 | $248,29716 claims |
| PfizerIbrance | $358 | $219,55714 claims |
| AbbVieVenclexta | $42 | $185,07112 claims |
| Lilly USA, LLCOlanzapine | $17 | $2716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Tulsa
- Simeon JaggernauthTulsa$116K
- Sagun ShresthaTulsa$4K
- Tariq MahmoodNorman$13K
- Muhammad FurqanOklahoma City$12K
- Sumbal NabiEnid$6K
- Aleda TomaOklahoma City$5K
- Manjula KrishnamurthiMuskogee$360
- Meredith LaroseOklahoma City$241
- Mathew CherianOklahoma City$196
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.